Clinical Trial Update: Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 safety study of a 21-valent pneumococcal conjugate vaccine in healthy infants starting at about 2 months of age.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 21-valent pneumococcal conjugate vaccine (Pneumococcal conjugate vaccine, 21-valent)

Snippet

Sponsor: Sanofi | Conditions: Pneumococcal Immunization | Phase 3 | Status: ACTIVE_NOT_RECRUITING